|Dr. Matteo Bertelli is the founder and president of the MAGI Group. MAGI Group is focused on the diagnosis, research and treatment of rare genetic diseases. It is operating in Europe (Italy, Belgium), European-neighbour (Tirana, Albania; Krasnoyarsk, Siberia) and African countries. MAGI established a project that offers study grants to young medical and biology graduates from developing countries.
Dr. Bertelli has graduated in Medicine from Brescia University in 1998. He presented his graduation thesis which was dedicated to experimental study in Tissue Engineering of skin substitute in collaboration with New Jersey University. He specialised in Medical Genetics at the same university and received PhD degree in Medical Biotechnologies in 2008 from Siena University. He conducted his doctoral thesis on Lesch-Nyhan syndrome in collaboration with Professor William Nyhan, La Jolla, University of California San Diego and Professor Massimo Pandolfo from Université Libre de Bruxelles.
Dr. Bertelli published about 60 papers in peer-reviewed journals with impact factors and has presented research results at many scientific conferences. He is a Member of the Board of Euro-Biotech Journal and EBTNA. His research focuses on genotypic and phenotypic variables of hereditary primary lymphedema, hereditary retinal dystrophies, hereditary vascular malformations, Mendelian non-syndromic obesity and hereditary metabolic diseases.
He is actively participating in the public health advocacy and scientific-divulgative events at national and international level. As an expert, he was involved in Italian Senate Motion on blindness and visual impairment to promote diagnostics, medical care and research. He is regularly participating in projects supported by European Council to ensure access to high-quality diagnostic services and reduce out-of-pocket diagnostic expenses and as a result, he was awarded the prize of Vice-President of European Council. As a National Counceller of Federazione Sanità, he was delegated various activities in Senate Chamber to discuss health care politics on genetic and rare diseases and access to comprehensive diagnostics, treatment and orphan drugs.